AB
JANX icon

Amalgamated Bank’s Janux Therapeutics JANX Stock Holding History

Amalgamated Bank’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,347
Closed -$19K – 2230
2025
Q4 		$19K Buy
1,347
+257
+24% +$6.04K ﹤0.01% 2129
2025
Q3 		$27K Hold
1,090
– – ﹤0.01% 2008
2025
Q2 		$25K Hold
1,090
– – ﹤0.01% 2028
2025
Q1 		$29K Buy
1,090
+120
+12% +$4.52K ﹤0.01% 1946
2024
Q4 		$52K Hold
970
– – ﹤0.01% 1829
2024
Q3 		$44K Hold
970
– – ﹤0.01% 1887
2024
Q2 		$41K Buy
970
+368
+61% +$17.3K ﹤0.01% 1899
2024
Q1 		$23K Sell
602
-985
-62% -$21.5K ﹤0.01% 2076
2023
Q4 		$17K Sell
1,587
-179
-10% -$1.55K ﹤0.01% 2719
2023
Q3 		$18K Hold
1,766
– – ﹤0.01% 2706
2023
Q2 		$21K Sell
1,766
-18
-1% -$241 ﹤0.01% 2713
2023
Q1 		$22K Sell
1,784
-398
-18% -$6.62K ﹤0.01% 2608
2022
Q4 		$29K Hold
2,182
– – ﹤0.01% 2635
2022
Q3 		$30K Hold
2,182
– – ﹤0.01% 2675
2022
Q2 		$27K Buy
2,182
+254
+13% +$3.01K ﹤0.01% 2765
2022
Q1 		$28K Buy
+1,928
New +$31.5K ﹤0.01% 2702

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Amalgamated Bank's JANX Position: Q1 2026 in Review

Amalgamated Bank sold out of Janux Therapeutics (JANX) in Q1 2026, closing a stake of 1,347 shares — an estimated $19K sold.

Amalgamated Bank first reported a position in JANX in Q1 2022 and held it in 16 quarters. The position peaked at $52K in Q4 2024. 190 funds tracked by Wall St. Rank hold JANX as of Q1 2026.

  • Amalgamated Bank reported no remaining Janux Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 1,347 Janux Therapeutics shares in Q1 2026, an estimated $19K.
  • Amalgamated Bank first reported a position in Janux Therapeutics in Q1 2022 and held it in 16 quarters.
  • Amalgamated Bank's Janux Therapeutics position peaked at $52K in Q4 2024.
  • 190 funds tracked by Wall St. Rank held Janux Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.